O ne vital goal of cancer research is a test that profiles individual tumors at the molecular level in order to guide treatment. Some single-marker predictive tests are now standard, as are two well-validated genomic prognostic tests for breast cancer. But for most tumors, such personalized tests are still viewed as futuristic. At a recent cancer molecular diagnostics conference, many genomic test methods were presented, all of them strictly experimental.
But since 2008, unknown to most oncologists and their patients, three companies have introduced commercial tests that provide genomic profi les of individual patients ' tumors. Along with the profi les, the companies include a list of drugs whose effi cacy has been associated, on some level, with the molecular features of each tumor. Marketing materials describe the tests as tools to help oncologists choose appropriate drugs or drug combinations.
These tests have gone largely unnoticed because the companies have relied mainly on limited direct marketing to oncologists and word of mouth for publicity. Only one company has published clinical results in a scientifi c journal. And because the labs that perform these tests are certifi ed under the federal Clinical Laboratory Improvement Amendments (CLIA), the tests do not require U.S. Food and Drug Administration approval to be sold. Fewer than 13,000 cancer patients have used them.
Unlike the "direct to consumer" genetic tests that assess risk for disease, results for these tests go fi rst to a doctor. But they have not yet proven better at guiding cancer treatment than standard methods. Their effectiveness has not been validated, and no randomized trials have taken place. Claims for their worth hinge on the argument that molecular profi ling information should translate to better treatment decisions, but no one knows yet whether that assumption is true. Critics argue that the tests should be used only to direct patients to clinical trials until the tests prove utility in their own randomized clinical trials. Such trials are planned, but these companies aren't waiting.
Three Tests, Three Approaches
The tests, in order of sales volume, are Caris Target Now from Caris Life Sciences in Irving, Texas; OncInsights from Intervention Insights in Grand Rapids, Mich.; and a profi ling service from GeneKey in Boston. All three tests take patient tumor tissue and, from it, generate a genomic profi le of the tumor, along with a list of potential drugs. But they vary widely in the methods they use and the information they provide. These methods, which are evolving, range from simply matching overexpressed genes with drugs to systems biology approaches that take into account complex signaling pathways and networks in tumor cells.
By far the most widely used test, with the most accepted methods, is Caris Target Target Now uses immunohistochemistry (the staining of tumor sections with antibodies against target proteins) to detect about 20 cancer-related proteins. It employs a standard Illumina oligonucleotide microarray to determine over-or underexpression of about 80 other genes. Biomarkers differ by tumor type and subtype. If needed, the test can use fl uorescence in situ hybridization, DNA sequencing, and PCR as well. The goal, in all cases, is to detect abnormal gene expression in the tumor. Aberrantly expressed genes are then matched with drugs on the basis of evidence from the scientifi c literature that response to a given drug is associated (or not) with the abnormalities. For example, high expression of HIF-1 has been associated with benefi t from bevacizumab, and low expression of PTEN has been associated with lack of benefi t from epidermal growth factor receptor inhibitors. The oncologist receives a report listing these drugs, together with the relevant citations in the literature, weighted according to strength of the evidence. "Think of it more as a literature aggregation profi ling platform than an isolated test," said Caris vice president Alan Wright, M.D., Ph.D.
The report recommends no specifi c treatment. "We would prefer that that fi nal analysis of candidacies for treatment be undertaken by the oncologist," he said. The test costs $3,400 and, according to Wright, is fully reimbursable from Medicare and from many private insurers.
OncInsights also uses gene expression to match tumors to drugs, but this test adds analytical methods designed to take advantage of knowledge of signaling pathways in tumors. OncInsights uses a standard Affymetrix chip to measure RNA expression of about 25,000 genes -essentially whole-genome coverage. The data are analyzed in several ways. Like Target Now, OncInsights incorporates simple biomarker rules -it identifi es markers that have been associated with response or resistance to certain drugs in published studies. In other cases, the test links gene expression levels to drugs that target those genes ' products, on the assumption that overexpression indicates drug sensitivity.
OncInsights also uses systems biology approaches. Because gene expression profi ling can't distinguish between "driver" genes, which actively promote tumor growth, and "passengers," which do not, systems biology incorporates knowledge of signaling pathways and networks. Algorithms assign "scores" to the networks or subnetworks according to their relevance to the growth of a particular tumor, on the basis of data from the patient's tumor. Algorithms then identify, within the tumor-relevant activated network(s), the most promising drug targets.
OncInsights also applies a "connectivity map" published by investigators at the Broad Institute in Cambridge, Mass., to match the expression pattern of a given patient's tumor with drugs that may alter expression of those genes, on the basis of cell line experiments. Using such drugs, "the logic is that you could reverse the genotype, hence the phenotype, of the cancer cell," said Webb.
In its report summary to the treating oncologist, Intervention Insights lists the drugs that appear using all these methodologies, along with a scoring of the evidence and background material. As with Target Now, there is no specifi c treatment recommendation. The test costs $3,950. Most insurance does not yet cover it.
GeneKey's service, at $30,000 -$35,000 each, is many times more expensive than Target Now and OncInsights. The test profi les the tumor genome through wholegenome mRNA expression profi ling and copy number variant detection. Wholeexome DNA sequencing is available as an add-on feature. The test was originally launched in 2008 by CollabRx in Palo Alto, Calif., and called CollabRx ONE, but the company spun off GeneKey earlier this year along with the eponymous test. Between 15 and 20 people have used the service so far, according to company chief scientist Raphael Lehrer, Ph.D. Because of the service's complexity, "we started out slowly to gain confi dence," said Lehrer.
"We're now ready to scale." Using wholeexome sequencing along with gene expression and copy number profi ling provides redundancy and thus greater confidence in the data, Lehrer said. Analysis is by proprietary systems biology approaches. "We're really looking across pathways -not just cancer pathways, but all known biological pathways," said Lehrer. "Sometimes we fi nd drugs that are not cancer related."
The test results, as for Target Now and OncInsights, do not include specifi c drug recommendations. "We call them 'hypotheses for discussion with the physician, ' " said Lehrer. "But we cast a much wider net for potential treatment approaches than either of them does." This discussion takes place in person with a scientifi c team dispatched from GeneKey to meet with the doctor and patient.
"With us sitting right there, it's pretty easy for the physician to fi gure out how to best apply our results," said Lehrer. 
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